- Hunter's Health Hacks
- Posts
- Join The GLP-1 Revolution
GLP-1 agonists are all the rage these days.
Unfortunately, most people have no clue about GLP-1 agonists.
To the majority of the population, GLP-1 agonists = Ozempic/Wegovy.
Most don’t even know about tirzepatide (even though Mounjaro’s received FDA approval).
Even worse, most of them do not know that other GLP-1 agonists exist.
Of course, you guys know better.
You know that Tirzepatide is currently the KING.
You know that Retatrutide is a very close second and has the mind-boggling ability to increase metabolism and ramp up fat burning.
And you know full well the impact that these agents can have on overall health.
But you know what’s crazy?
As tapped in as most of you are, I’d say that most of you STILL don’t fully understand the magnitude of what these agents will look like in the future 😳
Because if you think tirzepatide and retatrutide are impressive, you will be blown away when you see what’s currently in development…
So, for those of you not on his list, here’s a little peak at the intel Jay shared earlier this week:
A QUADRUPLE (yes, you heard that correctly) agonist targeting GLP-1, GIP, glucagon & IGF-1, making it easier to retain (and for people like us BUILD) lean muscle mass while simultaneously shredding fat
A GIP/glucagon dual agonist that’s better able to pull fat while preserving lean muscle, with about 20% coming from lean mass and 80% from fat in the clinical trials (now imaginable what it will do for people like us who actually train 💪)
HRS9531: A dual GLP-1/GIP agonist similar to tirzepatide that showed about 16.8% body weight reduction over just 24 short weeks
And this is just the next round.
Imagine what we’ll have in 5 years 😄
Now, with all these miracle compounds in the works, you may wonder why you should bother with tirzepatide at all.
After all, if all of these advances will blow tirzepatide and its contemporaries out of the water, what’s the point in stocking up now?
First of all, let me burst your bubble a bit (after I spent all that time getting you excited 😂).
Yes, all of these innovations are coming - and they’re coming SOON.
But they’re not coming TOMORROW.
Remember, we still have to navigate the post-tirzepatide landscape for the next few months (or even up to a year).
Call it “peptide purgatory,” where if you want GLP-1 agonists, you will be forced to use the vastly inferior semaglutide.
But you should also be stocking up on this stuff now for another reason:
The opportunity to make history.
I’m gonna let you in on a little secret:
Much of the “research” from clinical trials is an absolute joke.
Mediocre, substandard research is being done on mediocre, substandard research subjects.
It’s the fatal flaw of ALL research peer-reviewed clinical research…
The fact that it’s being conducted on a cohort of individuals who are in very, VERY poor health.
That’s what makes people like us unique.
For the first time, we now have the opportunity to test these new peptides and interventions on healthy individuals—OURSELVES.
This fact has led us to discover things that career researchers could never have imagined.
Take Tirzepatide as a prime example.
Who knew that micro-dosing was the ideal strategy for healthy individuals?
Or that it can be combined with Retatrutide to maximize the benefits of each while minimizing the downsides?
That’s just what Jay and I discovered last year.
Who knows what other discoveries and innovations we - and YOU - might uncover?
Yes, there are bigger and better things on the horizon.
And yes, in the grand scheme of things, they’re going to outperform Tirzepatide.
But I, for one, am not ready to leave this era of GLP-1 history behind without fully exploring the potential of this incredible agent.
In short, I want to help be a part of peptide history.
And if you want to be part of that history as well, I’d highly recommend acting NOW.
Remember, all vials of Tirzepatide MUST be liquidated by July 7th.
Click HERE to join or sign in to Limitless Life Nootropics VIP Peptide Club for access.
Best,
Hunter Williams